• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment

    12/15/21 4:43:22 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care
    Get the next $GWPH alert in real time by email

    Epileptic seizure frequency fell by an average of 86% among ten children treated with whole-plant medicinal cannabis, reveals a case series published in the open-access journal BMJ Paediatrics Open.

    None of the children had responded to other treatments, including the only cannabidiol (CBD) product licensed for their condition, reported medicalexpress.com

    Prompted by parents whose children had responded well to whole plant medicinal cannabis extracts, but not to conventional antiepileptic drugs or purified cannabidiol (CBD oil), medicinal (whole plant) cannabis was designated a prescription medicine for the treatment of severe childhood epilepsy in 2018. Whole plant cannabis includes THC, the main active ingredient of the plant associated with recreational use, CBD, and other neuroactive molecules such as terpenes.

    Researchers evaluated the use of whole plant medicinal cannabis in ten children whose severe epilepsy had not responded to conventional treatment, and two of whom hadn't responded to the only pharmaceutical grade, purified CBD oil licensed for the condition in children, Epidiolex, made by GW Pharmaceuticals plc (NASDAQ: GWPH). They wanted to assess and report the change in monthly seizure frequency and the impact of medicinal cannabis on changes in conventional epilepsy drug use.

    All the participants were recruited from two charities representing children using medicinal cannabis to treat their severe epilepsy. The children's average age was 6 but they ranged from 1 to 13 years.

    The children had tried an average of 7 conventional epilepsy drugs. After starting to take medicinal cannabis, this fell to an average of 1 each, with 7 of the children stopping them completely. Monthly seizure frequency reduced for all 10 children by an overall average of 86%.

    Full chemical analysis of the whole plant medicinal cannabis products used is ongoing, but researchers were able to assess the THC and CBD content.

    Parents and caregivers reported significant improvement in the health and wellbeing of their children, including in sleep, eating, behavior and cognition after they began to take whole-plant medicinal cannabis products. Only a few minor side effects, such as tiredness, were reported.

    Though this was an observational study involving a small number of participants, researchers highlighted that the new data suggest that whole-plant medicinal cannabis products are more effective than CBD products.

    Get the next $GWPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GWPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GWPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on GW Pharmaceuticals

    Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold

    2/22/21 7:29:26 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    GW Pharmaceuticals downgraded by Citigroup

    Citigroup downgraded GW Pharmaceuticals from Buy to Neutral

    2/4/21 11:27:13 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    GW Pharmaceuticals downgraded by HC Wainwright

    HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral

    2/4/21 7:30:03 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    $GWPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

    4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

    5/7/21 4:25:12 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

    4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

    5/7/21 4:21:57 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by GRYSKA DAVID W

    4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

    5/7/21 4:19:12 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    $GWPH
    SEC Filings

    View All

    SEC Form 15-12B filed by GW Pharmaceuticals Plc

    15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)

    5/17/21 6:09:29 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by GW Pharmaceuticals Plc

    S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

    5/5/21 5:27:52 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by GW Pharmaceuticals Plc

    S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

    5/5/21 5:26:02 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    $GWPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

    Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

    9/18/24 6:00:00 AM ET
    $IDYA
    $GWPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

    DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl

    5/5/21 9:15:00 AM ET
    $JAZZ
    $GWPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation

    LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the

    4/28/21 8:00:00 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    $GWPH
    Leadership Updates

    Live Leadership Updates

    View All

    IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

    Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

    9/18/24 6:00:00 AM ET
    $IDYA
    $GWPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $GWPH
    Financials

    Live finance-specific insights

    View All

    How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry

    LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR

    12/3/20 9:00:00 AM ET
    $TAP
    $MO
    $JNJ
    Beverages (Production/Distribution)
    Consumer Staples
    Medicinal Chemicals and Botanical Products
    Health Care

    $GWPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

    3/10/21 11:42:46 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

    2/16/21 3:58:07 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)

    2/16/21 11:42:06 AM ET
    $GWPH
    Major Pharmaceuticals
    Health Care